STOCKS TELEGRAPH

Tag: BFRI

  • 3 Stocks Investors Are Talking About: Biofrontera (BFRI), BGM Group (BGM), Cardiol Therapeutics (CRDL)

    3 Stocks Investors Are Talking About: Biofrontera (BFRI), BGM Group (BGM), Cardiol Therapeutics (CRDL)

    In today’s dynamic market environment, identifying early-stage companies with strong upside potential remains a key strategy for growth-focused investors. Particularly in the biotech sector, where innovation meets unmet medical needs, certain stocks are beginning to capture attention due to their clinical progress and improving financial metrics. A closer look at recent performers reveals several companies worth monitoring.

    Biofrontera Inc (BFRI)

    Biofrontera Inc (NASDAQ: BFRI) opened the trading on April 9, 2026, with great promise as it jumped 8.33% to $1.04. During the day, the stock rose to $1.05 and sunk to $0.98. Taking a more long-term approach, BFRI posted a 52-week range of $0.54-$1.19.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 44.08%. Meanwhile, its Annual Earning per share during the time was 44.08%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 96.63%. This publicly-traded company’s shares outstanding now amounts to $11.65 million, simultaneously with a float of $9.95 million. The organization now has a market capitalization sitting at $12.11 million.

    BGM Group Ltd (BGM)

    BGM Group Ltd (NASDAQ: BGM) started the day on April 9, 2026, with a price increase of 5.52% at $0.31. During the day, the stock rose to $0.32 and sunk to $0.29. Taking a more long-term approach, BGM posted a 52-week range of $0.27-$17.17.

    This publicly-traded company’s shares outstanding now amounts to $78.29 million, simultaneously with a float of $33.25 million. The organization now has a market capitalization sitting at $56.27 million. It’s Quick Ratio in the last reported quarter now stands at 1.33. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.10.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is expanding beyond a single-asset story by developing a diversified pipeline aimed at both niche and large-scale cardiovascular markets. This dual strategy allows the company to target near-term commercialization opportunities while building long-term value through broader indications such as heart failure.

    Market Momentum

    As of April 9, 2026, CRDL closed at $1.38, up 6.98%, with trading volume (737,505 shares) exceeding its average of 583,209—signaling increasing investor attention. With a market cap of $154.119M, the stock trades near the upper end of its 52-week range ($0.8730–$1.5900). A 1-year target estimate of $7.45 highlights significant upside potential, largely tied to upcoming clinical milestones.

    Pipeline Expansion: CRD-38

    Beyond CardiolRx™, the company is advancing CRD-38, a subcutaneous therapy targeting heart failure with preserved ejection fraction (HFpEF). This condition represents approximately half of all heart failure cases and currently lacks therapies that directly address inflammation. CRD-38 is being developed to target both inflammation and fibrosis, two key drivers of disease progression in HFpEF patients.

    Preclinical Foundation

    Early studies suggest that the active ingredient in CRD-38 may reduce cardiac fibrosis, prevent myocyte hypertrophy, and protect against functional decline. These findings support its potential as a disease-modifying therapy in a multi-billion-dollar market with significant unmet need.

    Outlook

    As CRD-38 advances toward clinical development, it could significantly expand Cardiol’s addressable market. Success in heart failure would position the company not only as a niche player in pericarditis but as a broader cardiovascular innovator.

  • Biofrontera Inc. (BFRI) Stock Keeps Winning

    Biofrontera Inc. (NASDAQ: BFRI) is a biopharmaceutical company that dabbles in the dermatology domain. The company specializes in the revolutionary and innovative area of photodynamic therapy. It enjoys strong sales given the popularity of its product, Ameluz, which is a prescription drug, used alongside the company’s RhodoLED lamp series. This star has a tremendous growth runway before it.

    Recent Biofrontera Milestones and Achievements

    Biofrontera Inc. (BFRI) had its IPO this year and has been on a roll ever since, achieving critical milestones in its short history. The company follows a data-driven sales strategy which is proving to be highly successful and gathering the company recognition from industrial giants. Biofrontera Inc. was listed, earlier during the year, by CIOCoverage Magazine as one of the most promising and high-growth life science companies to keep watch for in 2022. To add to shareholder’s delight, the company is continuously making new strides in photodynamic therapy, which could potentially position Biofrontera as a market-leading brand in dermatology.

    BFRI Strength in the Market

    In addition to recognition and milestones, BFRI has been taking the market by storm with its stellar performance. Its annual revenue figure of $24.1 million for 2021, is likely to grow to nearly $32 million by the end of this year, and as high as $45 million by next year. This is due to improving brand recognition for the Ameluz treatment, as well as tactical execution and sales momentum. The company is also strengthening its brand by simultaneously working on the protection of its intellectual property through patents, as well as educating the market on photodynamic treatment.

    Conclusion

    BFRI stock has excellent promise as well as all the substance to back up its ambitions. The industry recognizes it as an emerging champion owing to a reputation it has established through positive performance.

  • FDA Approval of Biofrontera Inc. (BFRI)’s Upsurge Falls Under Corrections After Hours

    Biofrontera Inc. (BFRI) shares soared high on April 13, as its Germany lab got approval from FDA for testing skin disease therapy Ameluz®. But the upsurge fell under corrections in the after-hours as the stock began to shed its gains.

    BRFI stock was valued at $4.76 a share in the after-hours session, following a decline of 4.03%. This decline came after the stock surged up by 34.05% in regular trading to close at $4.96 apiece.

    Source: BioSpace

    FDA’s Approval of BFRI Lab

    On Wednesday, the company announced that its cGMP laboratory has been approved by the U.S. FDA as a contract laboratory for Ameluz gel. Situated in Leverkusen, Germany, the lab will be responsible for batch control and stability testing of the gel. Moreover, stability testing is an essential component of the gel’s stability assurance.

    This approval will not only impart significant improvement in the manufacturing efficiency of the product but also control quality and provide the reliability of supply. In addition, the clearance also reduces dependence on third-party suppliers and production downtime along with product delays. Previously, the company was completely dependent on third-party providers and contract manufacturers for quality control.

    Penny Stocks and BFRI

    Penny stocks being under the value of $5 apiece, have always trended actively in times of any kind of instability in the market. With the widespread economical and geopolitical instability, penny stocks like ATER, NDRA, MDVL, LYRA, BFRI, etc. have been under the radar of investors.

    BFRI alone has accumulated over 80% last month and 40% in the past five days. Although the precursor of the gains has usually been news from the company, investors have not missed even the slightest opportunity to spike the stock up for making some profits.

    Company Overview

    Focused on dermatological products, the biopharma made its public debut last October. Post-IPO, the company entered 2022 with a cash balance of $24.5 million and increased its preliminary product revenue for Q1 2022 by over 100%. Furthermore, the company is currently working on achieving deeper sales penetration while its sales force is expected to begin in 2023.

    Having recovered from the impact of the pandemic by the end of 2021, BFRI is now looking forward to sales growth reaching pre-pandemic or even surpassing it.

    Conclusion

    Due to pipeline developments, strengthening of its leadership, and upbeat Q1 sales on top of beat 2021 earnings, BFRI has been bullish lately. The stock’s latest uptrend came from FDA approval of its lab which culminated in corrections.

  • Biofrontera Inc. (BFRI) stock Makes Some More Gains on Preliminary Product Revenues for Q1 2022

    Biofrontera Inc. (BFRI) stock Makes Some More Gains on Preliminary Product Revenues for Q1 2022

    On April 7, 2022, Biofrontera Inc. (BFRI) had another day full of gains with an increase of 14.12% in regular trading followed by 14.60% after hours. This bullishness has continued since the company announced its preliminary product revenue for the first quarter of fiscal 2022 on April 6. Thus, BFRI stock was trading at a per-share price of $4.63 in late trading after reaching $4.04 in the prior session.

    Source: Biofrontera

    The biopharmaceutical company specializes in the commercialization of dermatological products.

    BFRI’s Q1 2022 Revenue Expectations

    On Wednesday, the company shared its preliminary product revenue for Q1 2022 which ended on March 31. As per the calculations, the company is looking forward to product revenues between $9.5 and $10.0 million. This represents a humungous increase of 102%-113% YOY against the first quarter of 2021.

    Moreover, BFRI will be posting the complete Q1 2022 results in May 2022 while the 2021 year-end results are ready to be released on April 8, 2022. The 2021 earnings conference call will be hosted at 11:00 am Eastern Time on Friday.

    Market Developments

    The pharmaceutical industry while having an overall bullish outlook its topical drug delivery market is expected to surpass US$158.76 billion by 2028. Furthermore, the dermatology over-the-counter medication market is projected to grow at a 4.7% CAGR. The major driver for this CAGR of 5.83% is increased spending on dermatology as skin diseases continue to rise. Skin disease rank in 4th place as the most common cause of human illness globally. Some of the major causes of skin diseases include genetic factors, aging, and environmental factors.

    As per the latest news, FDA has proposed to rate pharmaceutical manufacturing companies. The U.S. FDA’s Office of Pharmaceutical Quality has proposed to develop a new rating system for assessing a company’s quality management maturity (QMM).

    BFRI’s Outlook

    The company’s Q1 2022 preliminary product sales have marked its strongest revenue quarter after the pandemic while being the second-strongest on record. This shows the company’s determination and continued efforts toward progress. Thus, with the continuous advancement of its pipeline and patent strategy along with strengthening its financial position, BFRI is looking forward to sustained growth.

    Conclusion

    Having posted a mammoth increase in its Q1 2022 sales, BFRI stock has continued making upward strides on Thursday. But 2021 year-end results are on the list for early morning on Friday, the stock may very well topple down if it did not impress the investors.